Third Coast Bancshares announced a quarterly cash dividend of $17.25 per share on its 6.75% Series A Convertible Non-Cumulative Preferred Stock. The dividend will be paid on October 15, 2026, to shareholders recorded by September 30, 2026. This move reflects the company's ongoing commitment to returning value to preferred shareholders. Third Coast Bancshares operates primarily in Texas through its subsidiary, Third Coast Bank, with 21 branches across major metropolitan areas.
Third Coast Bancshares' dividend announcement is presented here with a snapshot of the Financials sector on Pluang as of Sep 18, 2026 02:51 WIB. Among 74 priced US Financial stocks, 47 rose and 27 fell. MSCI led gains with a price of USD 551.13 and a 1-day change of +1.95%, contrasting with Nomura Holdings Inc at USD 10.26 down 1.87%, and Nerdwallet Inc at USD 9.24 down 1.81%.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
